获得性血友病A患者中的交叉反应性抗猪因子VIII抑制剂。
Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A.
作者信息
Stephen Maddie, Elbaz Carolyne, Hanif Hina, Pavenski Katerina, Teitel Jerry, Sholzberg Michelle
机构信息
Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, Division of Hematology/Oncology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
出版信息
Res Pract Thromb Haemost. 2024 Aug 22;8(6):102553. doi: 10.1016/j.rpth.2024.102553. eCollection 2024 Aug.
•Recombinant porcine factor VIII (rpFVIII) is a hemostatic treatment for bleeding in acquired hemophilia A.•The efficacy of rpFVIII can be negatively affected by cross-reacting anti-human FVIII antibodies.•In this cohort, 52% of patients with acquired hemophilia A had baseline cross-reacting antibodies.•Cross-reacting antibodies were associated with decreased FVIII activity levels post-rpFVIII infusion.
•重组猪因子VIII（rpFVIII）是治疗获得性血友病A出血的一种止血疗法。
•rpFVIII的疗效可能会受到交叉反应性抗人FVIII抗体的负面影响。
•在该队列中，52%的获得性血友病A患者有基线交叉反应性抗体。
•交叉反应性抗体与rpFVIII输注后FVIII活性水平降低有关。
Zotero 插件